Are you involved in selecting sequencing instruments or vendors (purchase, replacement, or expansion decisions)?

• Yes
• No

How would you best describe your practice?

• Academic
• Commercial
• Other specify

What is your primary role in sequencing decisions?

• Core facility manager
• Purchasing / procurement
• Clinician end-user (orders tests but does not select platforms)
• Bioinformatics lead
• Other (specify)

For the majority of your sequencing volume, the primary use case today is:

• Research / discovery
• Translational research
• Clinical diagnostics (regulated)
• Mixed, trending clinical
• Mixed, trending research

Which applications do you use sequencing for? Select all that apply.

• Oncology (tumor profiling / MRD)
• Germline / rare disease (WGS/WES)
• Infectious disease / metagenomics
• RNA-seq / single-cell
• Structural variants / repeat expansions
• Epigenetics / methylation
• De novo assembly / population genomics
• HLA / immunogenetics
• Other (specify)

Which sequencing modalities do you currently use? Select all that apply.

• Short-read sequencing
• Long-read sequencing
• Optical genome mapping (e.g., Bionano)
• Outsourced / send-out sequencing

What is your PRIMARY sequencing platform today for your highest-volume application?

• Illumina
• PacBio
• Oxford Nanopore
• Thermo Fisher (Ion Torrent)
• Other (specify)

For your highest-volume or most critical application, which platform do you expect will be PRIMARY in 12–24 months?

• Illumina
• PacBio
• Oxford Nanopore
• Thermo Fisher (Ion Torrent)
• Other (specify)

If you were constrained to ONE primary sequencing platform over the next 24 months, which would you choose?

• Illumina
• PacBio
• Oxford Nanopore
• Thermo Fisher (Ion Torrent)
• Other (specify)

And why would you choose [previous selection]?

Which platform would you be most likely to reduce or eliminate usage of over the next 24 months?

• Illumina
• PacBio
• Oxford Nanopore
• Thermo Fisher (Ion Torrent)
• Other (specify)

Is your organization planning to purchase or upgrade sequencing instruments in the next 24 months?

• Yes — replacement/refresh
• Yes — capacity expansion
• Yes — both above
• No planned purchase
• Not Sure

 Why is your organization planning to purchase or upgrade sequencing instruments? Please be specific.

What are the TOP TWO factors driving any change in your sequencing strategy? Select up to two.

• Accuracy / read quality
• Cost
• Turnaround time
• Read length
• Throughput
• Bioinformatics
• Vendor support / service reliability
• Regulatory or clinical validation
• Other, specify:

What is the single most important thing that has changed your sequencing strategy in the past 12 months?